NANBIOSIS opens in February the 1st competitive open call 2024 for its “Cutting-Edge Biomedical Solutions” and services.
NANBIOSIS is a research infrastructure for Biomedicine in which three cutting-edge public institutions collaborate forming a deeply interconnected laboratory network: CIBER-BBN, CCMIJU and IBIMA-Plataforma BIONAND. In addition, NANBIOSIS is part of the Spanish Map of ICTS (Spanish for “Scientific and Technical Unique Infrastructures”), approved by the Spanish Ministerio de Ciencia, Innovación y Universidades .
Our publicly funded facilities and internationally renowned scientist will help you design and test biomedical solutions to your heart’s content. We are open to all interested national and international users who may come either from the public or the private sector. You can apply to use our services in two modalities: under the “Competitive Open Access” (within two designated calls) or by “Access on Demand”, your choice.
To make that happen, at least 20% of the NANBIOSIS Units’ capacity is granted on the Competitive Open Access modality. The proposals granted under this modality will be prioritized according to criteria of scientific and technical quality and singularity. In addition, a 5% discount will be applied for those proposals that resort to at least one of our integrated services, the Cutting-Edge Biomedical Solutions.
There are 2 calls per year for Competitive Open Access that allow the prioritization of the best proposals. Click here to apply.
The next call will open on February 1st. The applications can be submitted throughout the whole month (due date February 29th). Access application forms submitted after that date will be processed under the “Access on Demand” modality.
Proposals granted in the Competitive Open Access modality must meet, at least, one of the circumstances listed in the access application form (“order request“), in order to demonstrate their scientific and technical quality or singularity.
Thus, for example, applications related to R&D projects funded through national or European calls are eligible. In addition, the proposals are required to use one of the NANBIOSIS “Cutting-Edge Biomedical Solutions”. That implies the interaction of at least two of our Units, which can be modified to your specific needs.
NANBIOSIS has worked with pharmaceutical companies of all sizes in the areas of drug delivery, biomaterials and regenerative medicine. Here are a few of them: